{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-22-000050","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.571668+00:00","generated_at":"2026-06-23T19:53:42.235611+00:00","sec_items":["7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Neurocrine to acquire Diurnal Group for £48.3M cash","bullets":["Acquiring entire issued share capital of Diurnal for ~£48.3M (~$56.5M) in an all-cash transaction.","Transaction conditional on approval by Diurnal shareholders and other customary closing conditions.","Neurocrine expects deal to accelerate establishment of UK clinical development and commercial capabilities.","Announcement made under Rule 2.7 of the UK City Code on Takeovers and Mergers."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-22-000050","json":"https://secwatch.observer/filing/0000914475-22-000050.json","markdown":"https://secwatch.observer/filing/0000914475-22-000050.md","text":"https://secwatch.observer/filing/0000914475-22-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000050/0000914475-22-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000050/nbix-20220830.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T19:53:42.235611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}